A novel series of potent and selective PDE5 inhibitors with potential for high and dose-independent oral bioavailability

Journal of Medicinal Chemistry

Volumn 49, Issue 12, 2006, Pages 3581-3594

  Allerton, Charlotte M N ^a   Barber, Christopher G ^a   Beaumont, Kevin C ^a   Brown, David G ^a   Cole, Susan M ^a   Ellis, David ^a   Lane, Charlotte A L ^a   Maw, Graham N ^a   Mount, Natalie M ^a   Rawson, David J ^a   Robinson, Colin M ^a   Street, Stephen D A ^a   Summerhill, Nicholas W ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 (5 ACETYL 2 BUTOXY 3 PYRIDINYL) 3 ETHYL 2 (1 ETHYL 3 AZETIDINYL) 3 ETHYL 2 (1 ETHYL 3 AZETIDINYL) 2,6 DIHYDRO 7H PYRAZOLO[4,3 D]PYRIMIDIN 7 ONE; CYTOCHROME P450 3A4; GLYCOPROTEIN P; KETOCONAZOLE; PHOSPHODIESTERASE; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; PHOSPHODIESTERASE VI; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; SILDENAFIL; SULFONAMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AQUEOUS SOLUTION; AREA UNDER THE CURVE; ARTICLE; CELL STRAIN CACO 2; CONTROLLED STUDY; CORPUS CAVERNOSUM; DOG; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG POTENCY; DRUG SELECTIVITY; DRUG SOLUBILITY; DRUG STRUCTURE; ERECTILE DYSFUNCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; LIVER CELL; NONHUMAN; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ADMINISTRATION, ORAL; ANIMALS; AZETIDINES; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; CRYSTALLOGRAPHY, X-RAY; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMPOTENCE; KETONES; MALE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PYRIMIDINES; PYRIMIDINONES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33745160705     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060113e     Document Type: Article

References (44)

1. For recent reviews on the pharmacological therapy for the treatment of erectile dysfunction, see: (a) Maw, G. N. Pharmacological therapy for the treatment of erectile dysfunction. Anna. Rep. Med. Chem. 1999, 34, 71-79.
2. (b) Cartledge, J.; Eardley, I. Viagra and beyond. Curt: Opin. CPNS Invest. Drugs 1999, 2, 240-245.
3. Eardley, I. The role of phosphodiesterase inhibitors in impotence. Expert Opin. Invest. Drugs 1997, 12 (6), 1803-1810.
4. Bunnage, M. E. Design and synthesis of selective PDE5 inhibitors for the treatment of MED. 224th ACS National Meeting, Boston, USA, August 18-22, 2002;
5. Bunnage, M. E. Highly selective chiral PDE5 inhibitors for treatment of MED. 227th ACS National Meeting, Anaheim, CA, March 28-April 1, 2004.
6. Bunnage, M. E. Viagra & Beyond: Selective PDE5 Inhibitors for Treatment of MED International Symposium on Advances in Synthetic, Combinatorial & Medicinal Chemistry, Moscow, Russia, May 5-8, 2004.
7. Chan, O. H.; Stewart, B. H. Physicochemical and drug-delivery considerations for oral drug bioavailability. Drug Discovery Today 1996, 1, 461-473.
8. Lipinski, C. A.; Lombardo, F.; Dominy, B.I W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 1997, 23, 3-25.
9. Walker, D. K.; Ackland, M. J.; James, G. C.; Muirhead, G. J.; Ranee, D. J.; Wastall, P.; Wright, P. A. Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica 1999, 29, 297-310.
10. Bunnage, M. E.; Mathias, J. P.; Street, S. D. A.; Wood, A. Preparation of pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction. PCT Int. Appl. WO 9954333.
11. Bunnage, M. E.; Mathias, J. P.; Street, S. D. A.; Wood, A. Preparation of pyrazolopyrimidinones as inhibitors of type 5 cyclic guanosine 3′,5′-monophosphate phosphodiesterase (cGMP PDE5) for the treatment of sexual dysfunction. PCT Int. Appl. WO 9849166.
12. Thomas, R. J.; Campbell, K. N.; Hennion, G. F. Catalytic hydration of alkylacetylenes. J. Am. Chem. Soc. 1938, 60, 718-720.
13. Wilds, A. L. Reduction with aluminium alkoxides (the Merwein-Pondorf- Verley reduction). Org. React. 1944, 2, 178-223.
14. Wright, S. W.; Hageman, D. L.; McClure, L. D. Synthesis of functionalised 3-pyridyl methyl ketones. J. Heterocycl. Chem. 1998, 35, 719-723.
15. Bell, A. S.; Brown, D.; Terrett, N. K. Preparation of pyrazolo[4,3-d/]pyrimidin-7-ones as cardiovascular agents. Eur. Pat. Appl. EP 463756.
16. Confirmed by nuclear Overhauser effect (see Experimental Section).
17. 50 values were determined using cone PDE6 derived from canine retina (unless otherwise stated), since this is the isozyme against which sildenafil shows least selectivity. Ballard, S. A.; Gingell, C. J.; Tang, K.; Turner, L. A.; Price, M. E.; Naylor, A. M. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J. Urol. 1998, 159, 2164-2171.
18. Abel, S.; Beaumont, K. C.; Crespi, C. L.; Eve, M. D.; Fox, L.; Hyland, R.; Jones, B. C.; Muirhead, G. J.; Smith, D. A.; Venn, R. F.; Walker, D. K. Potential role for P-glycoprotein in the non-proportional pharmacokinetics of UK-343,664 in man. Xenobiotica 2001, 31 (8/9), 665-676;
19. Walker, D. K.; Beaumont, K. C.; Comby, P.; Evans, K. M.; Gedge, J. I.; Halliday, R. C.; Roffey, S. J.; Wright, P. A. Pharmacokinetics and metabolism of a selective PDE5 inhibitor (UK-343,664) in rat and dog. Xenobiotica 2001, 31 (8/9), 651-664.
20. (a) Artursson, P. Epithelial transport of drugs in cell culture. I: A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells. J. Pharm. Sci. 1990, 79, 476-482.
21. (b) Stewart, B. H.; Chan, O. H.; Lu, R. H.; Reyner, E. L.; Schmid, H. L.; Hamilton, H. W.; Steinbaugh, B. A.; Taylor, M. D. Comparison of intestinal permeabilities determined in multiple in vitro and in situ models: Relationship to absorption in humans Pharm. Res. 1995, 12, 693-699.
22. (c) Bailey, C. A.; Bryla, P.; Malick, A. W. The use of the intestinal epithelial cell culture model, Caco-2, in pharmaceutical development Adv. Drug. Deliv. Rev. 1996, 22, 85-103.
23. app (cm/s) -amount transported/time × surface area × initial concentration: all data was measured at 25 μM unless otherwise stated; efflux ratio is the ratio of secretory flux to absorptive flux.
24. Carlille, D.; Zomorodi, K.; Houston, B. Scaling factors to relate drug metabolic clearance in hepatic microsomes isolated hepatocytes, and the intact liver Drug Met. Dispos. 1997, 25, 903-911.
25. Bell, A. S.; Terrett, N. K. Preparation of pyrazolopyrimidinones as cGMP phosphodiesterase inhibitors. Eur. Pat. Appl. EP 526004.
26. Aliquots of compounds are mixed with either phosphate buffer (pH 7.4) or water for > 16 h at room temperature or 37 °C. Soluble and insoluble compounds are separated by filtration or double centrifugation. The preferred method is filtration accompanied with an assessment of filter binding. Following separation, the pH of the soluble fraction is determined and the soluble material diluted in mobile phase for analysis by HPLC or MS. Bulk form is assessed by microscopy.
27. The stereoselectivity of the reduction of the 5′-ketone to the alcohol by ketone reductase was never determined. In addition, it was never identified whether reoxidation to the ketone occurred with the racemic alcohol or was specific to one of the enantiomers.
28. Chu-Moyer, M. Y.; Ballinger, W. E.; Beebe, D. A.; Coutcher, J. B.; Day, W. W.; Li, J.; Oates, P. J.; Weekly, R. M. SAR and species/ stereo-selective metabolism of the sorbitol dehydrogenase inhibitor, CP-470, 711. Bioorg. Med. Chem. Lett. 2002, 12(11), 1477-1480.
29. Felsted, R. L.; Bachur, N. R. Ketone reductases. Enzym. Basis Detoxicat. 1980, 1, 281-293.
30. Brown, D. G.; Groom, C. R.; Hopkins, A. L.; Jenkins, T. M.; Kamp, S. H.; O'Gara, M. M.; Ringrose, H. J.; Robinson, C. M.; Taylor, W. E. Crystal structures of human phosphodiesterase 5 and its ligand complex and their use in the design of site-directed mutants and design or screening of inhibitor compounds. PCT Int. Appl. WO 2003038080 Al.
31. Brown, D. G.; Groom, C. R.; Hopkins, A. L.; Jenkins, T. M.; Kamp, S. H.; O'Gara, M. M.; Ringrose, H. J.; Robinson, C. M.; Taylor, W. E. Crystal structures of human phosphodiesterase 5 and its ligand complex and their use in screening for inhibitor. PCT Int. Appl. WO 2004097010 Al.
32. Sung, B. J.; Hwang, K. Y.; Jeon, Y. H.; Lee, J. I., Heo, Y. S.; Kim, J. H.; Moon, J.; Yoon, J. M.; Hyun, Y. L. Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules. Nature 2003, 425 (6953), 98-102.
33. Taylor, E. C.; Wong, G. S. K. Convergent and efficient palladium-effected synthesis of 5,10-dideaza-5,6,7,8-tetrahydrofolic acid (DDATHF) J. Org. Chem. 1989, 54, 4 (15), 3618-3624.
34. Supplied by Key Organics.
35. Fox, D. N. A. Preparation of 1-benzoyl-3-piperidinylethylpiperidines and analogs as tachykinin receptor antagonists. Eur. Pat. Appl. EP 992493.
36. Jung, M. E.; Choi, Y. M. New Synthesis of 2-azetidines and 1-azabutadienes and the use of the latter in Diels-Alder reactions: total synthesis of (±)-γ-coniceine. J. Org. Chem. 1991, 56(24), 6729-30.
37. Greengrass, C. W.; Street, S. D. A.; Whittle, P. J. Preparation of antiviral peptide analogs PCT Int. Appl. WO 9319059.
38. Boolell, M.; Allen, M. J.; Ballard, S. A.; Gepi-Attee, S.; Muirhead, G. J.; Naylor, A. M.; Osterloh, I. H.; Gingell, C. Sildenafil: An orally active type 5 cyclic GMP specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int. J. Impotence Res. 1996, 8, 7-52.
39. Fawcett, L.; Baxendale R.; Stacey, P.; McGrouther, C.; Harrow I.; Soderling S.; Hetman, J.; Beavo, J. A.; Phillips, S. C. Molecular cloning and characterisation of a distinct human phosphodiesterase gene family: PDE11A. PNAS 2000, 97, 3702-3707.
40. Otwinowski, Z.; Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 1997, 276, 307-326.
41. Matthews, B. W. Solvent content of protein crystals. J. Mol. Biol. 1968, 33, 491-7.
42. Collaborative Computational Project Number 4. The CCP4 suite: Programs for protein crystallography. Acta Crystallogr., Sect. D: Biol. Crystallogr. D 1994, 50 (5), 760-763.
43. Quanta98, 1998, version 98.1111; Molecular Simulations Inc., San Diego, CA 92121-3752.
44. Brunger, A. T.; Adams, P. D.; Clore, G. M.; DeLano, W. L.; Gros, P.; Grosse-Kunstleve, R. W.; Jiang, J.-S.; Kuszewski, J.; Nilges, M.; Pannu, N. S.; Read, R. J.; Rice, L. M.; Simonson, T.; Warren, G. L. Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr., Sect. D: Biol. Crystallogr. D 1998, 54 (5), 905-921.